3 ms·
The problem is anti-biotics are no longer being developed. They could be developed but it is not finicially worth a large pharma to do so. Consider this, devel
by grahamm 10y ago
The problem is anti-biotics are no longer being developed. They could be developed but it is not finicially worth a large pharma to do so.
Consider this, development takes years (>10) and costs billions due to failed attempts (over 9 in 10 fail), testing, etc. They then go to market and no government will buy them because the price is high to recoup the billions spent developing over ten drugs which only one made to market. In the end the governments force the companies to sell them at a loss should there be an epidemic. Then to cap it all some company in another part of the world where IP is not honoured rips off the drug and floods the most needed places with a cheap knock off.
Where is the incentive for a pharma to go through this.
- d33 10y agoHow could the costs be driven down? Perhaps it's because FDA is overly cautious?
- grahamm 10y agoAnd before the FDA is over cautious the pharma is cautious. If they pushed a drug through that didn't work or caused serious side effects there would be legal implications that would wipe out some or all financial gains from the drug. Back to having no incentive.